683 Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

683 Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,000	Closed	-$186K	–	280
2023 Q1	$186K	Sell	27,000 -63,000	-70%	-$395K	0.01%	167
2022 Q4	$358K	Sell	90,000 -885,000	-91%	-$4.35M	0.03%	131
2022 Q3	$6.48M	Sell	975,000 -925,000	-49%	-$5.69M	0.5%	58
2022 Q2	$9.2M	Sell	1,900,000 -32,829	-2%	-$200K	0.65%	52
2022 Q1	$18.1M	Hold	1,932,829	–	–	0.97%	31
2021 Q4	$23M	Buy	1,932,829 +2,900	+0.2%	+$33.5K	0.84%	27
2021 Q3	$22M	Hold	1,929,929	–	–	0.86%	30
2021 Q2	$34.6M	Buy	1,929,929 +36,529	+2%	+$588K	1.2%	18
2021 Q1	$29.3M	Buy	1,893,400 +72,251	+4%	+$1.05M	1.55%	18
2020 Q4	$22.2M	Buy	1,821,149 +849,431	+87%	+$11.8M	1.05%	21
2020 Q3	$12.5M	Buy	971,718 +740,372	+320%	+$6.39M	0.91%	24
2020 Q2	$2.35M	Hold	231,346	–	–	0.19%	75
2020 Q1	$1.88M	Hold	231,346	–	–	0.22%	72
2019 Q4	$2M	Sell	231,346 -43,654	-16%	-$245K	0.23%	59
2019 Q3	$1.7M	Sell	275,000 -75,000	-21%	-$606K	0.19%	68
2019 Q2	$5.81M	Hold	350,000	–	–	0.53%	46
2019 Q1	$5.85M	Buy	350,000 +12,500	+4%	+$180K	0.53%	45
2018 Q4	$3.88M	Buy	337,500 +62,500	+23%	+$1.26M	0.23%	69
2018 Q3	$11M	Sell	275,000 -25,000	-8%	-$711K	0.71%	36
2018 Q2	$8.48M	Hold	300,000	–	–	0.57%	38
2018 Q1	$4.58M	Buy	300,000 +162,500	+118%	+$3.87M	0.41%	53
2017 Q4	$4.49M	Buy	+137,500	New	+$3.71M	0.38%	69

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

683 Capital Management's MRNS Position: Q2 2023 in Review

683 Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 27,000 shares — an estimated $186K sold.

683 Capital Management first reported a position in MRNS in Q4 2017 and held it in 22 quarters. The position peaked at $34.6M in Q2 2021. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

683 Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 27,000 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $186K.
683 Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 22 quarters.
683 Capital Management's Marinus Pharmaceuticals, Inc position peaked at $34.6M in Q2 2021.
106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.